Control of disease activity with large extended-interval dosing of rituximab/ocrelizumab in highly active pediatric multiple sclerosis-Reference-Cited by-同舟云学术

Control of disease activity with large extended-interval dosing of rituximab/ocrelizumab in highly active pediatric multiple sclerosis

Published:2024-01-02 Issue:2 Volume:30 Page:261-265
ISSN:1352-4585
Container-title:Multiple Sclerosis Journal
language:en
Short-container-title:Mult Scler

Author:

Venet Melany¹²,Lepine Anne³,Maarouf Adil¹^ORCID,Biotti Damien⁴⁵^ORCID,Boutiere Clémence¹,Casez Olivier⁶,Cohen Mikael⁷^ORCID,Durozard Pierre⁸,Demortière Sarah¹,Giorgi Laetitia⁹¹⁰,Maillart Elisabeth¹¹^ORCID,Mathey Guillaume¹²,Mazzola Laure²,Rico Audrey¹,Camdessanche Jean-Philippe²,Deiva Kumaran⁹¹⁰,Pelletier Jean¹,Audoin Bertrand¹¹³^ORCID

Affiliation:

1. Department of Neurology, Aix Marseille Univ, APHM, Hôpital de la Timone, CNRS, CRMBM, Marseille, France

2. Neurology Department, University Hospital, Saint-Etienne, France

3. Paediatric Neurology Department, Assistance Publique des Hôpitaux de Marseille, Hôpital Universitaire, Marseille, France

4. Centre Ressources et Compétences Sclérose en Plaques (CRC-SEP) et Service de Neurologie B4, Hôpital Pierre-Paul Riquet, CHU Toulouse Purpan, Toulouse, France

5. INSERM UMR1291-CNRS UMR5051, Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity), Université Toulouse 3, Toulouse, France

6. Neuro-inflammatory Disease Center, Centre Hospitalier Universitaire de Grenoble Alpes, Grenoble, France

7. CRC-SEP CHU Nice, UR2CA-URRIS, Université Nice Cote d’Azur, Hôpital Pasteur 2, Nice, France

8. Centre Hospitalier d’Ajaccio, Ajaccio, France

9. Department of Paediatric Neurology, National Reference Center for Rare Inflammatory and auto-immune Brain and Spinal Diseases, Hopitaux Universitaires Paris-Saclay, Hôpital Bicêtre, Le Kremlin-Bicetre, France

10. UMR 1184, Immunology of Viral Infections and Autoimmune Diseases, Universite Paris Saclay, Le Kremlin-Bicetre, France

11. Department of Neurology, National Reference Center for Rare Inflammatory and auto-immune Brain and Spinal Diseases, Pitie Salpetriere Hospital, APHP, Paris, France

12. Neurology Unit, University Hospital of Nancy, Hôpital Central, Nancy Cedex, France

13. Pôle de Neurosciences Cliniques, Service de Neurologie, Aix Marseille Univ, APHM, Hôpital de la Timone, Marseille, France

Abstract

Recent studies in adults suggested that extended-interval dosing of rituximab/ocrelizumab (RTX/OCR) larger than 12 months was safe and could improve safety. This was an observational cohort study of very active pediatric-onset multiple sclerosis (PoMS) (median (range) age, 16 (12–17) years) treated with RTX/OCR with 6 month standard-interval dosing ( n = 9) or early extended-interval dosing ( n = 12, median (range) interval 18 months (12–25)). Within a median (range) follow-up of 31 (12–63) months after RTX/OCR onset, one patient (standard-interval) experienced relapse and no patient showed disability worsening or new T2-weighted lesions. This study suggests that the effectiveness of RTX/OCR is maintained with a median extended-interval dosing of 18 months in patients with very active PoMS.

Publisher

SAGE Publications

Link

http://journals.sagepub.com/doi/pdf/10.1177/13524585231223069

Reference18 articles.

1. Paediatric multiple sclerosis and antibody-associated demyelination: clinical, imaging, and biological considerations for diagnosis and care

2. What does first-line therapy mean for paediatric multiple sclerosis in the current era?

3. Real‐World Effectiveness of Initial Disease‐Modifying Therapies in Pediatric Multiple Sclerosis

4. Use of newer disease-modifying therapies in pediatric multiple sclerosis in the US

5. Demographic Features and Clinical Course of Patients With Pediatric-Onset Multiple Sclerosis on Newer Disease-Modifying Treatments

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anti-CD20 therapies for pediatric-onset multiple sclerosis: A systematic review;Multiple Sclerosis and Related Disorders;2024-11

2. B-cell Depletion Therapy in Pediatric Neuroinflammatory Disease;Current Neurology and Neuroscience Reports;2024-09-11

3. Safety and effectiveness of disease-modifying therapies after switching from natalizumab;Multiple Sclerosis Journal;2024-07

4. Old and New Strategies in the Treatment of Pediatric Multiple Sclerosis: A Personal View for a New Treatment Approach;Neurology and Therapy;2024-06-01